Page last updated: 2024-10-26

brl 42810 and Acquired Immunodeficiency Syndrome

brl 42810 has been researched along with Acquired Immunodeficiency Syndrome in 3 studies

Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.

Research Excerpts

Excerpt	Relevance	Reference
"We examined a 41-year-old man with AIDS but without a history of varicella-zoster virus dermatitis who had disciform corneal edema in his left eye."	1.30	Disciform keratitis: a case of herpes zoster sine herpete. ( Chandler, D; Margolis, TP; Neger, R; Silverstein, BE, 1997)

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (66.67)	18.2507
2000's	1 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Whitley, RJ	1
Klein, JL	1
Sandy, C	1
Migdal, CS	1
Main, J	1
Silverstein, BE	1
Chandler, D	1
Neger, R	1
Margolis, TP	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
An Open Label Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants[NCT00942084]			Phase 1	32 participants (Actual)	Interventional	2011-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Clearance (CL)

"Timeframe:~Version 1:0-5 min,2-4 hrs,6-8 hrs post doses 1 and 5-15; prior to doses 5-15 Version 2:0-15 min post doses 1 and 5-15; within 30 min prior to doses 2 and 5-15; 2-3 hrs post doses 5-15; 15-18 hrs post last dose" (NCT00942084)
Timeframe: V1:0-5 min,2-4 hrs,6-8 hrs post Doses 1&5-15;prior to doses 5-15; V2:0-15 min post doses 1&5-15; within 30 min prior to doses 2&5-15; 2-3 hrs post doses 5-15; 15-18 hrs post last dose

Intervention	L/h/kg (Median)
Acyclovir Study Design	0.278

Half-life (T1/2)

(NCT00942084)
Timeframe: up to 3 days of study drug administration and 10 days of safety monitoring

Intervention	h (Median)
Acyclovir Study Design	7.07

Maximum Steady State Concentration (Cmaxss)

(NCT00942084)
Timeframe: up to 3 dasy of study drug administration and 10 days of safety monitoring

Intervention	mg/L (Median)
Acyclovir Study Design	11.1

Minimum Steady State Concentration (Cminss)

(NCT00942084)
Timeframe: up to 3 days of study drug administration and 10 days of safety monitoring

Intervention	mg/L (Median)
Acyclovir Study Design	4.15

Steady State Concentration at 50% of the Dosing Interval (C50ss)

(NCT00942084)
Timeframe: up to 3 days of study drug administration and 10 days of safety monitoring

Intervention	mg/L (Median)
Acyclovir Study Design	6.33

Volume of Distribution (V)

(NCT00942084)
Timeframe: up to 3 days of study drug administration and 10 days of safety monitoring

Intervention	L/kg (Median)
Acyclovir Study Design	3.34

Reviews

1 review available for brl 42810 and Acquired Immunodeficiency Syndrome

Article	Year
Herpes simplex virus infection. Seminars in pediatric infectious diseases, 2002, Volume: 13, Issue:1 Topics: 2-Aminopurine; Acquired Immunodeficiency Syndrome; Acyclovir; Administration, Oral; Adult; Antiviral	2002

Other Studies

2 other studies available for brl 42810 and Acquired Immunodeficiency Syndrome

Article	Year
Famciclovir in AIDS-related acute retinal necrosis. AIDS (London, England), 1996, Volume: 10, Issue:11 Topics: 2-Aminopurine; Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Famciclovir; Foscarnet;	1996
Disciform keratitis: a case of herpes zoster sine herpete. American journal of ophthalmology, 1997, Volume: 123, Issue:2 Topics: 2-Aminopurine; Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Corneal Edema; DNA, Vira	1997